Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1

Abstract Background Arsenic trioxide (ATO) is commonly used in the treatment of acute promyelocytic leukemia (APL), but does not benefit patients with solid tumors. When combined with other agents or radiation, ATO showed treatment benefits with manageable toxicity. Previously, we reported that metf...

Description complète

Détails bibliographiques

Auteurs principaux:	Sunbin Ling, Haiyang Xie, Fan Yang, Qiaonan Shan, Haojiang Dai, Jianyong Zhuo, Xuyong Wei, Penghong Song, Lin Zhou, Xiao Xu, Shusen Zheng
Format:	Artigo
Langue:	Inglês
Publié:	BMC 2017-02-01
Collection:	Journal of Hematology & Oncology
Sujets:	Metformin Arsenic trioxide Intrahepatic cholangiocarcinoma mTORC1 p38 MAPK ERK3
Accès en ligne:	http://link.springer.com/article/10.1186/s13045-017-0424-0
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!